Palvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Truist Financial Analyst Says

Palvella Therapeutics (NASDAQ:PVLA) had its price objective raised by Truist Financial from $56.00 to $80.00 in a report issued on Thursday morning, Marketbeat.com reports. Truist Financial currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on PVLA. Oppenheimer initiated coverage on shares of Palvella Therapeutics in a report on Tuesday, September 9th. They set an “outperform” rating and a $85.00 target price for the company. Canaccord Genuity Group raised their target price on shares of Palvella Therapeutics from $52.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, August 19th. Lifesci Capital initiated coverage on shares of Palvella Therapeutics in a report on Monday, August 4th. They set an “outperform” rating and a $90.00 target price for the company. Stifel Nicolaus raised their target price on shares of Palvella Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Finally, Chardan Capital raised their target price on shares of Palvella Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $69.27.

Palvella Therapeutics Stock Down 0.9%

Shares of PVLA opened at $62.63 on Thursday. The company has a 50-day simple moving average of $50.92 and a 200-day simple moving average of $33.81. The company has a market capitalization of $692.69 million, a PE ratio of -5.18 and a beta of -0.13. Palvella Therapeutics has a 52-week low of $11.17 and a 52-week high of $65.57.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, research analysts anticipate that Palvella Therapeutics will post -3.69 EPS for the current year.

Institutional Investors Weigh In On Palvella Therapeutics

Several hedge funds have recently modified their holdings of PVLA. Citadel Advisors LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter worth about $125,000. Spire Wealth Management acquired a new stake in shares of Palvella Therapeutics during the 1st quarter worth about $70,000. Strid Group LLC acquired a new stake in shares of Palvella Therapeutics during the 1st quarter worth about $818,000. Royce & Associates LP acquired a new stake in shares of Palvella Therapeutics during the 1st quarter worth about $2,002,000. Finally, Frazier Life Sciences Management L.P. boosted its position in shares of Palvella Therapeutics by 5.5% in the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock worth $19,313,000 after acquiring an additional 36,120 shares during the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.